Innovative Translational Studies in Cholestatic Disorders | AASLD

Innovative Translational Studies in Cholestatic Disorders

Nov 09 2025
Convention Center: Room 202, Level 2
11:00 AM - 12:30 PM

World Class Speakers

Kazumichi Abe, MD, PhD
Abstract Presenter

Kazumichi Abe, MD, PhD

Fukushima Medical University School of Medicine
Monika Sarkar, MD, FAASLD, MAS
Abstract Presenter

Monika Sarkar, MD, FAASLD, MAS

University of California, San Francisco
David N. Assis, MD
Abstract Presenter

David N. Assis, MD

Yale University
Monika Sarkar, MD, FAASLD, MAS
Moderator

Monika Sarkar, MD, FAASLD, MAS

University of California, San Francisco
David N. Assis, MD
Moderator

David N. Assis, MD

Yale University

Description

Deeper investigations into the pathogenesis of AIH, PBC and PSC requires application of novel tools.  This session highlights new discoveries in human and pre-clinical models of autoimmune and cholestatic disorders by the application of modern sophisticated analyses.

Journey Maps

Presentations

11:00 AM - 11:15 AM
Aug 28 2026
Convention Center - Room 202, Level 2

Single-nuclei RNA sequencing of human liver identifies cell type signatures that distinguish autoimmune hepatitis from disease controls

Kazumichi Abe, MD, PhD , Abstract Presenter
Cholestatic and Autoimmune
11:15 AM - 11:30 AM
Aug 28 2026
Convention Center - Room 202, Level 2

Candida albicans Contributes to Liver Fibrosis in Primary Sclerosing Cholangitis

Monika Sarkar, MD, FAASLD, MAS , Abstract Presenter
Cholestatic and Autoimmune
11:30 AM - 11:45 AM
Aug 28 2026
Convention Center - Room 202, Level 2

Role of the autophagy inhibitor Rubicon in a PSC mouse model

David N. Assis, MD , Abstract Presenter
Cholestatic and Autoimmune
11:45 AM - 12:00 PM
Aug 28 2026
Convention Center - Room 202, Level 2

Identification of BST2, IL18R1, IL4R, and KCNJ11 as associated with pruritus response to elafibranor in patients with primary biliary cholangitis: Proteomic results from the ELATIVE® trial

Kazumichi Abe, MD, PhD , Abstract Presenter
Cholestatic and Autoimmune
12:00 PM - 12:15 PM
Aug 28 2026
Convention Center - Room 202, Level 2

Identification of anti-DOK2 antibodies in patients with autoimmune hepatitis via a human protein microarray

Kazumichi Abe, MD, PhD , Abstract Presenter
Cholestatic and Autoimmune
12:15 PM - 12:30 PM
Aug 28 2026
Convention Center - Room 202, Level 2

Spatially resolved single-cell analysis of PSC liver explants reveals niche-specific disease effects.

David N. Assis, MD , Abstract Presenter
Cholestatic and Autoimmune

Objectives

  • Outline the roles played by multiple cell types in the pathogenesis of PBC and PSC.
  • Discuss the findings from new investigations into targets for AIH.
  • Describe the potential roles for fungal products as contributors to the pathogenesis of PSC.